Lathambiopharm-deprecated
-
Industries
Products
Non-dilutive Funding
Assistance in securing funding from government agencies and opportunities without diluting company ownership.
Product Development
Support across all stages of product development for vaccines, therapeutics, cell and gene therapies, and medical devices.
Strategic Consulting
Consulting services including pipeline and portfolio analysis, market research, and financial modeling.
Government Relations
Facilitation of interactions with government entities to support product development and funding.
Proposal Development
Assistance in creating proposals for securing funding and project support.
Post-award Support
Support services following the award of funding, ensuring compliance and project success.
Non-dilutive Funding
Assistance in securing funding from government agencies and opportunities without diluting company ownership.
Product Development
Support across all stages of product development for vaccines, therapeutics, cell and gene therapies, and medical devices.
Strategic Consulting
Consulting services including pipeline and portfolio analysis, market research, and financial modeling.
Government Relations
Facilitation of interactions with government entities to support product development and funding.
Proposal Development
Assistance in creating proposals for securing funding and project support.
Post-award Support
Support services following the award of funding, ensuring compliance and project success.
Expertise Areas
- Cell and gene therapy development
- Vaccine development
- Therapeutic product development
- Bioprocessing and biomanufacturing
Key Technologies
- Viral vector manufacturing
- Autologous cell therapy (CAR-T) manufacturing
- Point-of-care diagnostic platforms
- AI-enabled diagnostics and decision support
Key People
Principal Consultant 1
Senior Consultant
Senior Analyst
Managing Director
Consultant 3
Associate Manager
Principal Consultant 1
Senior Consultant
Senior Analyst
Managing Director
Consultant 3
Associate Manager
News & Updates
Patrick Falvey, Principal Consultant at LBG, was featured in the American Pharmaceutical Review for his expertise on global biomanufacturing trends.
An article discussing the potential of cytokines in cancer immunotherapy, focusing on the research of SON-1010, an albumin-binding IL-12 fusion protein.
LBG has been awarded a grant to develop a platform for global health cost modeling.
Public Health Vaccines has initiated the first clinical trial for its Marburg virus vaccine.
LBG has been awarded a contract by NIAID for preclinical services, valued at up to $30 million.
Patrick Falvey, Principal Consultant at LBG, was featured in the American Pharmaceutical Review for his expertise on global biomanufacturing trends.
An article discussing the potential of cytokines in cancer immunotherapy, focusing on the research of SON-1010, an albumin-binding IL-12 fusion protein.
LBG has been awarded a grant to develop a platform for global health cost modeling.
Public Health Vaccines has initiated the first clinical trial for its Marburg virus vaccine.
LBG has been awarded a contract by NIAID for preclinical services, valued at up to $30 million.